PS
NGM

Peter Svennilson’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Peter Svennilson’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$287M Buy
18,017,932
+310,954
+2% +$5.67M 23.39% 1
2020
Q2 		$350M Buy
17,706,978
+383,834
+2% +$7.34M 29.23% 1
2020
Q1 		$214M Buy
17,323,144
+902,315
+5% +$14.7M 27.04% 1
2019
Q4 		$304M Buy
16,420,829
+253,922
+2% +$3.71M 36.26% 1
2019
Q3 		$224M Buy
16,166,907
+472,816
+3% +$7.1M 69.59% 1
2019
Q2 		$230M Buy
+15,694,091
New +$230M 65.66% 1

Other funds holding NGM

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.49B AUM 18.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Peter Svennilson's NGM Position: Q3 2020 in Review

Peter Svennilson increased its NGM Biopharmaceuticals, Inc. Common Stock (NGM) stake by 1.8% in Q3 2020, buying an estimated $5.67M and bringing the position to 18,017,932 shares worth $287M. The position accounts for 23.39% of the portfolio, ranked #1.

Peter Svennilson first reported a position in NGM in Q2 2019 and has held it in 6 quarters since. The position peaked at $350M in Q2 2020. 81 funds tracked by Wall St. Rank hold NGM as of Q3 2020.

  • Peter Svennilson held 18,017,932 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $287M as of Q3 2020.
  • Peter Svennilson bought 310,954 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $5.67M.
  • NGM Biopharmaceuticals, Inc. Common Stock made up 23.39% of Peter Svennilson's portfolio in Q3 2020, its #1 holding.
  • Peter Svennilson first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and has held it in 6 quarters since.
  • Peter Svennilson's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $350M in Q2 2020.
  • 81 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Peter Svennilson's 13F filing for Q3 2020, filed 4 Nov 2020.